Scroll

nefopam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1891	13669-70-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nefopam fenazoxine (+/-)-Nefopam nefopam hydrochloride nefopam HCl	Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26) Molecular weight: 253.35 Formula: C17H19NO CLOGP: 2.91 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 12.47 ALOGS: -3.50 ROTB: 1

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nefopam
fenazoxine
(+/-)-Nefopam
nefopam hydrochloride
nefopam HCl

Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26)

Molecular weight: 253.35
Formula: C17H19NO
CLOGP: 2.91
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 12.47
ALOGS: -3.50
ROTB: 1

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	34 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	3 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.04 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	36 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	5.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	12 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	5 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1978	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular injury	371.17	25.81	124	5339	27257	63456302
Cholestasis	335.19	25.81	117	5346	29317	63454242
Hepatic cytolysis	136.70	25.81	51	5412	15356	63468203
Acute kidney injury	135.18	25.81	138	5325	263277	63220282
Acute generalised exanthematous pustulosis	125.65	25.81	44	5419	11055	63472504
Drug reaction with eosinophilia and systemic symptoms	95.28	25.81	50	5413	33786	63449773
Thrombocytopenia	88.05	25.81	85	5378	151072	63332487
Coma	72.45	25.81	53	5410	64311	63419248
Foetal megacystis	70.81	25.81	10	5453	26	63483533
Drug dependence	65.56	25.81	35	5428	24448	63459111
Pancreatitis acute	64.88	25.81	36	5427	27130	63456429
Tonic clonic movements	61.98	25.81	16	5447	1419	63482140
Fatigue	58.25	25.81	5	5458	888023	62595536
Metabolic acidosis	57.34	25.81	40	5423	45029	63438530
Peripheral nerve injury	56.86	25.81	12	5451	439	63483120
Anticholinergic syndrome	53.95	25.81	16	5447	2366	63481193
Shock haemorrhagic	47.20	25.81	21	5442	9874	63473685
Mixed liver injury	46.86	25.81	17	5446	4718	63478841
Miosis	46.31	25.81	19	5444	7334	63476225
Spinal epidural haemorrhage	45.93	25.81	8	5455	102	63483457
Hyperkalaemia	40.29	25.81	35	5428	54168	63429391
Cell death	40.04	25.81	13	5450	2588	63480971
Encephalopathy	39.40	25.81	30	5433	38590	63444969
Epidural haemorrhage	38.25	25.81	7	5456	120	63483439
Myoclonus	37.80	25.81	21	5442	15847	63467712
Shock	37.48	25.81	24	5439	23439	63460120
Drug ineffective	37.36	25.81	22	5441	1044743	62438816
Urinary bladder rupture	36.91	25.81	7	5456	147	63483412
Somnolence	35.89	25.81	59	5404	178626	63304933
Hyponatraemia	35.69	25.81	46	5417	111854	63371705
Eosinophilia	35.66	25.81	23	5440	22733	63460826
Granulomatous liver disease	35.18	25.81	9	5454	769	63482790
Hyperlactacidaemia	34.95	25.81	12	5451	2837	63480722
Anaphylactic shock	34.87	25.81	23	5440	23610	63459949
Cutaneous T-cell lymphoma	34.46	25.81	10	5453	1370	63482189
Pancreatic pseudoaneurysm	34.34	25.81	6	5457	78	63483481
Foetal heart rate abnormal	31.93	25.81	8	5455	629	63482930
Naevus haemorrhage	31.68	25.81	6	5457	125	63483434
Stevens-Johnson syndrome	31.38	25.81	22	5441	24928	63458631
Agranulocytosis	31.23	25.81	22	5441	25112	63458447
Neutropenia	30.16	25.81	54	5409	174951	63308608
Epidural analgesia	30.01	25.81	5	5458	48	63483511
Porphyria	29.98	25.81	6	5457	168	63483391
Poisoning deliberate	29.91	25.81	16	5447	11202	63472357
Blood phosphorus decreased	29.73	25.81	12	5451	4441	63479118
Prescription drug used without a prescription	29.07	25.81	10	5453	2376	63481183
Livedo reticularis	28.89	25.81	10	5453	2422	63481137
Pain	28.74	25.81	14	5449	740614	62742945
Confusional state	28.73	25.81	63	5400	236317	63247242
Autonomic nervous system imbalance	27.45	25.81	10	5453	2808	63480751

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Agranulocytosis	203.25	29.28	83	3958	23738	34929152
Drug reaction with eosinophilia and systemic symptoms	155.82	29.28	76	3965	32936	34919954
Cholestasis	154.66	29.28	71	3970	26877	34926013
Rash maculo-papular	150.98	29.28	71	3970	28380	34924510
Hepatocellular injury	135.24	29.28	61	3980	22150	34930740
Eosinophilia	131.63	29.28	63	3978	26159	34926731
Confusional state	91.33	29.28	97	3944	144063	34808827
Alveolar lung disease	84.11	29.28	17	4024	369	34952521
Pulmonary interstitial emphysema syndrome	78.93	29.28	17	4024	507	34952383
Toxic skin eruption	65.21	29.28	30	4011	11355	34941535
Pancytopenia	63.63	29.28	66	3975	95091	34857799
Hyperleukocytosis	60.64	29.28	18	4023	1984	34950906
Diffuse alveolar damage	58.07	29.28	18	4023	2296	34950594
Urethral valves	52.93	29.28	11	4030	275	34952615
Acute kidney injury	52.28	29.28	111	3930	304877	34648013
Mixed liver injury	50.27	29.28	17	4024	2856	34950034
Eosinophilic pneumonia	46.98	29.28	17	4024	3484	34949406
Hyperammonaemia	46.83	29.28	20	4021	6347	34946543
Anaphylactic shock	44.73	29.28	26	4015	15915	34936975
Oesophageal achalasia	43.87	29.28	10	4031	388	34952502
Consciousness fluctuating	41.81	29.28	12	4029	1175	34951715
Haemolytic anaemia	40.17	29.28	21	4020	10458	34942432
Hallucination, visual	34.64	29.28	23	4018	17768	34935122
Generalised oedema	34.18	29.28	20	4021	12388	34940502
Hepatic encephalopathy	33.57	29.28	21	4020	14664	34938226
Hepatitis	32.89	29.28	25	4016	23879	34929011
Amnesia	32.68	29.28	26	4015	26537	34926353
Pancreatitis acute	29.29	29.28	25	4016	28116	34924774

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular injury	465.37	22.55	185	9408	47408	79687387
Cholestasis	452.54	22.55	186	9407	51923	79682872
Drug reaction with eosinophilia and systemic symptoms	231.38	22.55	125	9468	64119	79670676
Agranulocytosis	206.27	22.55	103	9490	44927	79689868
Acute kidney injury	158.18	22.55	248	9345	519156	79215639
Eosinophilia	156.97	22.55	86	9507	45259	79689536
Hepatic cytolysis	148.04	22.55	70	9523	27081	79707714
Rash maculo-papular	142.54	22.55	87	9506	55991	79678804
Acute generalised exanthematous pustulosis	130.75	22.55	56	9537	17198	79717597
Thrombocytopenia	102.54	22.55	142	9451	265117	79469678
Confusional state	96.64	22.55	152	9441	317845	79416950
Mixed liver injury	90.01	22.55	34	9559	7544	79727251
Pancreatitis acute	89.26	22.55	62	9531	49542	79685253
Toxic skin eruption	84.68	22.55	45	9548	22248	79712547
Pulmonary interstitial emphysema syndrome	78.26	22.55	17	9576	506	79734289
Alveolar lung disease	76.60	22.55	17	9576	560	79734235
Fatigue	75.87	22.55	11	9582	929716	78805079
Coma	74.09	22.55	75	9518	100574	79634221
Anaphylactic shock	69.50	22.55	47	9546	35949	79698846
Drug dependence	61.96	22.55	46	9547	40723	79694072
Tonic clonic movements	61.95	22.55	19	9574	2245	79732550
Pancytopenia	58.41	22.55	85	9508	165660	79569135
Encephalopathy	56.61	22.55	54	9539	67343	79667452
Hyperleukocytosis	55.21	22.55	18	9575	2592	79732203
Hepatitis	53.28	22.55	48	9545	55679	79679116
Drug ineffective	50.91	22.55	34	9559	1080879	78653916
Diffuse alveolar damage	49.52	22.55	18	9575	3586	79731209
Miosis	49.27	22.55	28	9565	15761	79719034
Cell death	48.37	22.55	19	9574	4680	79730115
Peripheral nerve injury	47.37	22.55	12	9581	702	79734093
Neutropenia	46.40	22.55	105	9488	287605	79447190
Haemolytic anaemia	46.13	22.55	28	9565	17792	79717003
Febrile bone marrow aplasia	43.10	22.55	24	9569	12996	79721799
Anticholinergic syndrome	42.15	22.55	16	9577	3595	79731200
Metabolic acidosis	40.85	22.55	50	9543	82479	79652316
Gamma-glutamyltransferase increased	40.66	22.55	41	9552	54639	79680156
Shock haemorrhagic	40.65	22.55	27	9566	20033	79714762
Eosinophilic pneumonia	39.44	22.55	17	9576	5293	79729502
Hyperammonaemia	38.23	22.55	21	9572	11072	79723723
Oesophageal achalasia	36.61	22.55	10	9583	784	79734011
Urinary retention	35.91	22.55	39	9554	56591	79678204
Hyperthermia	35.88	22.55	24	9569	18013	79716782
Consciousness fluctuating	35.35	22.55	12	9581	1957	79732838
Spinal epidural haemorrhage	34.56	22.55	7	9586	147	79734648
Hyperbilirubinaemia	33.57	22.55	26	9567	24492	79710303
Pneumonia	33.44	22.55	19	9574	660227	79074568
Foetal heart rate abnormal	33.28	22.55	8	9585	376	79734419
Pain	33.22	22.55	22	9571	703780	79031015
Myoclonus	32.89	22.55	27	9566	27633	79707162
Poisoning deliberate	32.60	22.55	23	9570	18805	79715990
Pancreatic pseudoaneurysm	32.33	22.55	6	9587	78	79734717
Epidural haemorrhage	31.89	22.55	7	9586	219	79734576
Hepatic encephalopathy	31.73	22.55	25	9568	24141	79710654
Hallucination, visual	30.90	22.55	28	9565	32701	79702094
Prothrombin time ratio decreased	30.65	22.55	9	9584	916	79733879
Naevus haemorrhage	29.67	22.55	6	9587	125	79734670
Hyperlactacidaemia	29.17	22.55	14	9579	5581	79729214
Hallucination	28.76	22.55	43	9550	85702	79649093
Transaminases increased	28.31	22.55	33	9560	51710	79683085
Epidural analgesia	28.15	22.55	5	9588	50	79734745
Generalised oedema	27.88	22.55	23	9570	23686	79711109
Headache	27.53	22.55	23	9570	653749	79081046
Porphyria	26.91	22.55	6	9587	202	79734593
Status epilepticus	26.79	22.55	23	9570	25018	79709777
Renal failure	26.60	22.55	68	9525	200900	79533895
Hallucinations, mixed	26.40	22.55	14	9579	6885	79727910
Dizziness	25.43	22.55	16	9577	526425	79208370
Bicytopenia	25.31	22.55	12	9581	4658	79730137
Cutaneous T-cell lymphoma	24.59	22.55	10	9583	2693	79732102
Blood phosphorus decreased	24.02	22.55	13	9580	6655	79728140
Somnolence	23.88	22.55	73	9520	238908	79495887
Granulomatous liver disease	23.44	22.55	8	9585	1325	79733470
Target skin lesion	23.14	22.55	5	9588	145	79734650
Respiratory gas exchange disorder	22.68	22.55	7	9586	844	79733951

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N02BG06	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Other analgesics and antipyretics
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:35640	adrenergic uptake inhibitors
CHEBI has role	CHEBI:50949	SSRI
CHEBI has role	CHEBI:51039	dopamine reuptake inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.85	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Sodium channel protein type 5 subunit alpha	Ion channel	Q14524	SCN5A_HUMAN			WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	Ki	7.54	PDSP
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	Ki	7.48	PDSP
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	Ki	5.77	PDSP
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN	Ki	6.48	PDSP
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	Ki	7.25	PDSP
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	Ki	6.28	PDSP

External reference:

ID	Source
N0000167217	NUI
D05133	KEGG_DRUG
C0027556	UMLSCUI
CHEBI:88316	CHEBI
CHEMBL465026	ChEMBL_ID
DB12293	DRUGBANK_ID
D009340	MESH_DESCRIPTOR_UI
4450	PUBCHEM_CID
3018	INN_ID
23327-57-3	SECONDARY_CAS_RN
4UP8060B7J	UNII
4324	RXNORM
001582	NDDF
004636	NDDF
322300008	SNOMEDCT_US
350324006	SNOMEDCT_US
419768004	SNOMEDCT_US
CHEMBL1407915	ChEMBL_ID

Pharmaceutical products:

None